Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer

Exclusion Criteria

• •1. Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study.
• •2. Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.
• •3. Inability to provide informed consent.
• •MSC Recipients
• •1. Prior radiation therapy to the prostate.
• •2. Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study.
• •3. Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.
• •4. Inability to provide informed consent.
• •5. Any active autoimmune disease requiring treatment (e.g. steroid, disease-modifying antirheumatic drugs, biologic agents, etc.).
• •6. Prior history of penicillin or streptomycin allergy.
• •7. No prior history of deep venous thrombosis or pulmonary embolism within 5 years prior to enrollment in the study.
• •8. Abnormal liver function (bilirubin, AST, ALT ≥ 3 x upper limit of normal)
• •9. Abnormal kidney function (serum creatinine ≥ 2 x upper limit of normal)
• •10. Abnormal cardiac function as manifested by NYHA (New York Heart Association) class III or IV heart failure or history of a prior myocardial infarction (MI) within the last five years prior to enrollment in the study.
• •11. History of symptomatic pulmonary dysfunction.